Tryptophan hydroxylase (TPH), being the rate-limiting enzyme in the biosynthesis of serotonin plays a major role as candidate gene in several psychiatric disorders. Recently, a second TPH isoform (TPH2) was identified in mice, which was exclusively present in the brain. In a previous post-mortem study of our own group, we could demonstrate that TPH2 is also expressed in the human brain, but not in peripheral tissues. This is the first report of an association study between polymorphisms in the TPH2 gene and major depression (MD). We performed singlenucleotide polymorphism (SNP), haplotype and linkage disequlibrium studies on 300 depressed patients and 265 healthy controls with 10 SNPs in the TPH2 gene. Significant association was detected between one SNP (P ¼ 0.0012, global P ¼ 0.0051) and MD. Haplotype analysis produced additional support for association (Po0.0001, global P ¼ 0.0001). Our findings provide evidence for an involvement of genetic variants of the TPH2 gene in the pathogenesis of MD and might be a hint on the repeatedly discussed duality of the serotonergic system. These results may open up new research strategies for the analysis of the observed disturbances in the serotonergic system in patients suffering from several other psychiatric disorders.
Major depression (MD) is one of the most common psychiatric diseases with a lifetime prevalence between 5 and 17%. 1 Although environmental components have been demonstrated, genetic factors account for 40-70% of the risk for developing MD. 2 However, specific genes or relevant DNA sequence variations involved in the pathogenesis of MD have not yet been identified.
Several lines of evidence indicate that disturbances of the central serotonergic system are involved in the pathophysiology of affective disorders. Tryptophan hydroxylase (TPH), the rate-limiting enzyme in the synthesis of the neurotransmitter serotonin (5-HT), 3 is widely discussed as a major candidate gene in many psychiatric disorders, especially depression and suicidal behavior. 4, 5 Numerous studies about genetic variants or different expression levels of the TPH gene related to depression, schizophrenia, alcoholism, drug abuse, aggression and sucidality have been reported, but none of them have led to convincingly confirmed results up to now. [6] [7] [8] [9] Until recently only one gene encoding TPH, in the following referred as first tryptophan hydroxylase isoform (TPH1), was described for vertebrates. TPH1 is located on chromosome 11p15.3-p16, spans a region of 29 kb and harbors 11 exons. 10 To elucidate the physiological impact of the loss of serotonin (5-HT), the group of Walther et al 11 generated mice genetically deficient for TPH1, and found that these mice still express normal amounts of 5-HT in the brain (hippocampus and frontal cortex). This observation confirmed the repeatedly discussed hypothesis of a second TPH isoform. 12, 13 Using the TPH1 sequence as a query in a screening procedure of the Human Genome Database, the group of Walter et al 11 identified a new TPH isoform which they designated as second tryptophan hydroxylase isoform (TPH2) or neuronal TPH. The expression of both isoforms is partially exclusive. We were recently able to demonstrate that in humans TPH1 and TPH2 are expressed in nearly equal amounts in several brain regions (frontal cortex, thalamus, hippocampus, hypothalamus and amygdala), with a predominant expression of TPH2 in the brain stem, the major locus of the serotonin-producing neurons, whereas TPH1 mRNA is exclusively present in peripheral tissues such as the heart, lung, kidney, duodenum, liver and adrenal gland.
14 The human TPH1 and TPH2 genes are highly homologous proteins exhibiting 71% of amino-acid identity. 15 All structural and functional important sequences of TPH1 are conserved in TPH2, which suggests that most of the TPH1 features should also be present in TPH2. The human TPH2 gene is located on chromosome 12q15, comprises 11 exons and covers a region of 93.5 kb. Considering the above-mentioned findings, the TPH2 gene represents a new and interesting, so far not yet investigated candidate gene for affective disorders.
A previous screening approach in our own group with a few validated single-nucleotide polymorphism (SNPs) in the TPH2 gene detected an association between MD and the SNP rs1386494 (unpublished data). Therefore, the aim of the present study was to investigate a probable role of polymorphisms around this significant SNP in the TPH2 gene in the etiology of MD. We performed association and linkage disequilibrium (LD) studies on 300 patients suffering from MD and 265 healthy controls with 10 SNPs in this region of the TPH2 gene spanning approximately 28 kb between exons 5 and 7. To enhance the detection power of association, we also compared the estimated haplotype frequencies deduced from genotype frequencies of the 10 SNPs.
Material and methods

Subjects
A total of 300 unrelated Caucasian patients with MD (114 males, 186 females) hospitalised in the Psychiatric Department of the Ludwig-Maximilians-University Munich and diagnosed according to the DSM-IV and ICD-10 criteria were included in the study. All patients were interviewed by experienced psychiatrists using the Structured Clinical Interview for DSM-IV disorders (SCID-I). 16 Severity of depression was assessed using the 17-item Hamilton Rating Scale for Depression (HAMD-17) and the Clinical Global Impression Scale (CGI). Only subjects with a minimum score of 18 on the HAMD-17 entered the study. Patients with severe organic disorders were excluded to avoid cases with secondary depression. We have further excluded all patients being comorbid for other psychiatric disturbances (eg substance/alcohol dependence, personality disorders, anxiety disorders). In the patient sample, there were significantly more females than males as compared with the control sample (62/38 vs 48/52%; P ¼ 0.001, w 2 ¼ 11.3, df ¼ 1). As there were no significant differences concerning all other investigated variables (age, clinical variables such as CGI and HAMD-17 scores), males and females were not analyzed separately. Patient history, family history and demographic data of patients and controls are given in Table 1 .
In all, 265 ethnically matched subjects from the general population in Southern Germany (138 males, 127 females) served as control group. All probands were psychiatrically screened using personality questionnaires (MMPI, NEO-FI, TCI) and a short structured interview with a psychiatrist to rule out psychiatric problems. Probands with known history of psychiatric disorders were excluded from the study. All patients and controls were of Caucasian origin from the German population and came from the same geographical area in southern Germany.
The local ethics committee approved the study protocol; patients and controls were included in the study after they gave written informed consent.
Genotyping
Genomic DNA was isolated from whole blood according to standard procedures. Since the TPH2 gene is highly homologous to the TPH1 gene, especially in the coding regions (exons), we have only chosen intronic SNPs to avoid coamplification of TPH1 gene sequences. In addition, the TPH2 specificity of the primers was tested by a BLAST search applying the ENSEMBL BLAST VIEW program (http://www.ensembl.org/Multi/blastview).
The 10 SNPs in the TPH2 gene were genotyped using the snapshot methodology (Applied Biosystems, Foster City, CA, USA). This is a commercially available mini sequencing method that relies on the extension of a primer immediately adjacent to the SNP using fluorescently labeled dideoxy nucleotides. The fluorescently labeled extension primers can then be visualized by electrophoresis on a capillary PRISM 310 automated sequencer (Applied Biosystems). Turner et al 17 provides a good overview about this method. Detailed information on PCR primers and extension primer sequences as well as reaction PCR conditions can be obtained on request. Data were processed by using Genscan Analysis version 3.7 and Genotyper version 3.7 (Applied Biosystems)
All laboratory procedures were carried out blind to case-control status.
Statistics All genotyping results were tested for Hardy-Weinberg equilibrium (HWE) applying the HWSIM computer program (http://krunch.med. yale.edu/hwsim).
Association analysis and haplotypes frequency estimation was performed with the computer program COCAPHASE 2.35 (http://www.hgmp.mrc.ac.uk). 18 This package calculates likelihood ratio tests under a log-linear model of the probability that an allele or haplotypes belong to the case rather than the control group, using a standard unconditional logistic The TPH2 gene in major depression P Zill et al regression. The expectation maximization (EM) algorithm is used to resolve uncertain haplotypes and provides maximum-likelihood estimates of frequencies. Since the EM algorithm does not accurately estimate haplotypes frequencies below 1%, haplotypes o1% in both groups were not considered. The global null hypothesis that all odds ratios are equal was tested by permutation. This method randomly reassigns the case and control labels in the actual data and gives a significance level corrected for all markers or haplotypes tested. A total of 10 000 permutations were performed in each permutation analysis. In the case of a significant global test, individual haplotypes were tested for association by grouping all others together and applying the w 2 test with 1 df. Calculation of pair wise LD between the SNPs was carried out using the ARLEQUIN 2.0 program (http:// lgb.unige.ch/arlequin). 19 We used D 0 to describe the magnitude of LD 20 and w 2 square values for allelic association (calculated by the Arlequin program) to determine if the D 0 -value was statistically significant (if the null hypothesis of no LD could be rejected).
The significance level for all statistical tests was 0.05. We applied Bonferroni corrections for all multiple tests. Power was estimated with the help of Table  8 in Longmate et al. 21 
Nucleotide sequences
The SNP are named in the present study according to the ID numbers from the SNP database (http:// www.ncbi. nlm.nih.gov/SNP/). Position of the SNPs was taken from the Genbank contig: accession number NT_029419 (http://www.ncbi.nlm.nih.gov/).
Results
We performed an association study with 10 SNPs in the TPH2 gene and compared 300 patients suffering from MD with 265 healthy controls. All SNPs were found to be in HWE in both the cases and control samples.
Single-marker association analysis
The results of the single SNP association analysis are presented in Table 2 . Statistically significant evidence for association with MD was detected. A global Pvalue of 0.0051 was obtained by permutation analysis. The SNP rs1386494 yielded the most significant result, due to an increase of the G-allele in the cases (0.79 vs 0.86; P ¼ 0.0012; P ¼ 0.012 after Bonferroni correction). A marginal significant P-value of 0.0496 was observed for the SNP rs1843809 (not significant after correction). All other SNPs were found to be not associated with the disorder. Power analysis showed that for the detection of a main effect for one of the polymorphisms with a relative risk of 2 or greater, given the disorder-related gene frequency of 0.30, assuming a dominant model of inheritance, a test size of a ¼ 0.05 and a power of 80%, a sample size of 193 subjects would have been large enough. Therefore we had sufficient power to detect such an effect.
Inter-marker LD
The standardized measure of LD denoted as D 0 , as well as the corresponding P-values were calculated for all pairs of SNPs on both the cases and the controls. Tables 3 and 4 show these data. The LD pattern is fairly identical in both samples and nearly Haplotype analysis A 10-marker haplotype analysis was performed with all 10 SNPs across the TPH2 gene. Table 5 demonstrates the frequencies for the estimated 10-marker haplotypes among patients and controls. We observed three major haplotypes that account for 85% of all possible marker combinations in the patient sample, respectively, and 90% in the control sample. A significant evidence for association with MD was provided by a global P-value of 0.0001. Individual haplotype tests by examining the distribution differences for each haplotype showed that distinct haplotypes differ highly significant between cases and controls. These observations result from different distributions of the haplotypes 3, 4 and 5. Haplotype 3 is twice as frequent in the controls (w 2 ¼ 16.52, df ¼ 1, Po0.0001), whereas the haplotypes 4 and 5 exist only in the sample of patients and appear with frequencies of 5% (w 2 ¼ 25.80, df ¼ 1, Po0.0001) and 4% (w 2 ¼ 21.09, df ¼ 1, Po0.0001), respectively. Considering the higher heritability of recurrent depression than single episode depression, 22 we have additionally analyzed these two groups separately. In 25% of the included patients, it was the first episode of disease, the other 75% had several episodes. This separate evaluation showed no significant differences 
Discussion
This is the first report of an association study, applying SNP, LD and haplotype analysis of the newly identified TPH2 gene with 300 patients suffering from MD (MD) and 265 healthy controls. Significant association was detected in single-marker and haplotype tests, with statistically significant global P-values based on permutation procedures that account for the multiple markers and haplotypes tested (single SNP analysis: P ¼ 0.0051; haplotypes test: P ¼ 0.0001).
In the single SNP evaluation, we found a statistically significant association of SNP rs1386494 (P ¼ 0.0012) and a marginal relation of SNP rs1843809 (P ¼ 0.0496) with MD (not corrected for multiple testing). Using the Bonferroni correction, only rs1386494 remained statistically significant (P ¼ 0.012). It has to be mentioned that the Bonferroni procedure is a very conservative correction as some of the SNPs are in LD and therefore the tests are not independent. However, given that the investigated SNPs are common in the general population and with regard to the heterogeneity of MD, it is probable that single SNPs do not represent the primary basis of the disease, but rather SNP combinations should be considered.
On the other hand, conclusive results were obtained from the 10-marker haplotype analysis. Several haplotypes showed significant evidence for an association with MD. For the haplotype analysis, the global null hypothesis that all odds ratios are equal were also tested by permutation, owing to the fact that the estimated haplotype frequencies cannot be treated as observed data (P ¼ 0.0001). Two major haplotypes that only differ in the bases of SNP rs4760815 (ATATGGCAGA/T) account for 77% (MD) and 74% (CON) of all possible marker combinations. Three haplotypes differed significantly in their distribution between patients and controls with P-values o0.0001. These P-values remained significant after Bonferroni correction for the number of SNPs. Haplotype 3 (CGGCAATGAT) is twice as frequent in the controls (16 vs 8%), whereas the haplotypes 4 (ATACGACGAT) and 5 (CGGTAGTAGA) occurred only in the sample of patients and appear with frequencies of 5 and 4%, respectively. These results imply several possibilities. One of them is that the haplotypes 4 and 5 carry one or more genetic variants predisposing to MD. Conversely, it is also possible that the haplotype 3 contains variants that are protective against the illness.
To estimate LD between pairs of SNPs, we used Lewontin's D. 20 D 0 has been shown to be reasonably robust towards differences in allele frequencies in contrast to D, 23 but could also be 1 if one of the two alleles is present on other haplotypes as well. 24 Therefore, we also examined the corresponding P-values. The LD pattern as well as the significance of LD between all the SNP combinations is fairly identical in both samples and shows the often observed block pattern in the genome, which can be explained by the existence of a few common Table 2 based on the physical marker order: rs1386488, rs1843809, rs2220330, rs1386495, rs1386494, rs6582072, rs1386493, rs1386492, rs4760814 and rs4760815.
haplotypes that account for most of the haplotype diversity. 25 Nearly all D 0 -values were statistically significant except the pairs SNP A (rs1386488)-SNP G (rs1386493), SNP A (rs1386488)-SNP J (rs4760815) in the sample of the cases and SNP A (rs1386488)-SNP J (rs4760815), SNP E (rs1386494)-SNP J (rs4760815) in the control sample. The absence of LD suggests that a putative recombination hotspot might lie between these SNPs. 26 The power of the above-mentioned haplotype analysis is dependent on LD between relevant markers. Simulation studies have estimated the length of useful LD to be as low as 3 kb, 27 whereas LD more than 60 kb from common alleles was observed in 19 randomly selected genomic regions. 28 Therefore, we should have sufficient power in our haplotypes study.
The results of our study suggest that polymorphisms in the TPH2 gene and distinct haplotypes of 10 SNPs, which cover approximately 28 kb between exons 5 and 7, represent risk factors in the development of MD. However, the possibility that a susceptibility locus lies in other parts of the TPH2 gene needs to be examined with more polymorphisms, since the size of the gene (495 kb) by far exceeds the investigated region in the present study.
A possible limitation of the present study is the fact that all case-control association studies have a risk of false-positive findings due to population stratification, 29 although the extent to which such stratification actually contributes to false-positive findings is controversial. 30 Further studies with so called 'parent-child trios' are needed to circumvent these problems and to confirm our results.
Since more than 30 years, there was evidence for the existence of isoforms of TPH, which was supported by the following observations (for review see Walther and Bader 15 ): in total brain protein preparations two peaks of activity with different isoelectric points were detected; different TPH enzymes were described depending on their activity and analyzed tissues; immunochemical investigations found different detection rates in several tissues; different mRNA and protein levels were present in pineal gland and the raphe nuclei. Taken together, all efforts undertaken to identify TPH isoforms were unfruitful due to the lack of differentiating molecular probes and antibodies. The recent identification of the new TPH2 isoform offers now new possibilities in the study of disorders with disturbances in the serotonergic system and provides further clinical implications. Own results in our group of a post-mortem study with human brain tissues revealed that TPH2 mRNA is expressed in several brain regions (frontal cortex, thalamus, hippocampus, hypothalamus and amygdala), but not in peripheral tissues such as heart, lung, kidney, duodenum, liver and adrenal gland. 14 Further experiments have shown that the mRNA expression of TPH1 and TPH2 in these brain regions is nearly identical except in the brain stem, the major locus of the serotonin producing neurons, where TPH2 is the predominately gene (unpublished data).
Moreover, it has been found that TPH1 mRNA is also present in peripheral tissues. Interestingly, TPH1 knockout mice have shown normal serotonin levels in the brain and no behavioral alterations were detectable, although the peripheral 5-HT pools were almost depleted. 11 These findings might implicate a duality of the serotonergic system with peripheral serotonergic effects determined by TPH1 and the CNS effects regulated by TPH2, including a partially uncoupling of behavioral effects from TPH1.
The result of the present study might provide evidence for the model of differentially regulated peripheral and central serotonergic systems. To our knowledge, this is the first report about a positive association between genetic variants in the TPH2 and MD. Numerous studies with polymorphisms in the TPH1 gene in psychiatric disorders have tried to link genetic variants to such diseases, but the results remain inconclusive. [6] [7] [8] [9] The negative outcome of most of these studies is not surprising if one considers that TPH1 is probably not expressed in brain stem at considerable levels.
These interpretations are certainly at the moment very speculative. Possible interactions between TPH1 and TPH2 should also be considered as modulating mechanisms in the pathogenesis of MD and disorders related to disturbances of the serotonin system. This could also account for the conflicting results with the TPH1 gene in several psychiatric disorders. The potential functional consequences of the investigated SNPs, as well as possible interactions between the TPH2 gene and other plausible candidate genes, as the TPH1 gene in determining the susceptibility to MD require further studies in order to understand the genetic factors underlying MD.
